UCB Provides Update on U.S. Regulatory Review of Bimekizumab

Brussels (Belgium), 19 September 2023– UCB, a global biopharmaceutical company, today provided an update on the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis. UCB has...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news